Incyte Corporation (0J9P.L)
USD 58.02
(-0.72%)
USD 58.02
(-0.72%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 620.52 Million USD | 7.09% |
| 2022 | 579.44 Million USD | -1.08% |
| 2021 | 585.77 Million USD | 343.78% |
| 2020 | -240.29 Million USD | -159.77% |
| 2019 | 402 Million USD | 211.09% |
| 2018 | 129.22 Million USD | 153.02% |
| 2017 | -243.73 Million USD | -268.09% |
| 2016 | 144.99 Million USD | 186.27% |
| 2015 | 50.65 Million USD | 1154.35% |
| 2014 | -4.8 Million USD | 70.17% |
| 2013 | -16.1 Million USD | -1502.61% |
| 2012 | 1.14 Million USD | 100.8% |
| 2011 | -143.18 Million USD | -1119.17% |
| 2010 | 14.04 Million USD | 110.05% |
| 2009 | -139.76 Million USD | 12.26% |
| 2008 | -159.28 Million USD | -86.78% |
| 2007 | -85.28 Million USD | -10.95% |
| 2006 | -76.86 Million USD | 23.73% |
| 2005 | -100.78 Million USD | 32.29% |
| 2004 | -148.85 Million USD | 0.3% |
| 2003 | -149.29 Million USD | -52.49% |
| 2002 | -97.9 Million USD | -51.33% |
| 2001 | -64.69 Million USD | -3.37% |
| 2000 | -62.59 Million USD | -131.81% |
| 1999 | -27 Million USD | -321.31% |
| 1998 | 12.2 Million USD | 64.86% |
| 1997 | 7.4 Million USD | 225.42% |
| 1996 | -5.9 Million USD | 46.36% |
| 1995 | -11 Million USD | 9.09% |
| 1994 | -12.1 Million USD | -146.94% |
| 1993 | -4.9 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 146.08 Million USD | 130.61% |
| 2024 Q1 | 91.89 Million USD | -50.93% |
| 2024 Q2 | -477.23 Million USD | -619.31% |
| 2023 Q3 | 214.7 Million USD | 10.8% |
| 2023 FY | 620.52 Million USD | 7.09% |
| 2023 Q4 | 187.27 Million USD | -12.78% |
| 2023 Q1 | 90.45 Million USD | -12.06% |
| 2023 Q2 | 193.78 Million USD | 114.23% |
| 2022 Q1 | 116.54 Million USD | 5.24% |
| 2022 FY | 579.44 Million USD | -1.08% |
| 2022 Q4 | 102.85 Million USD | -25.67% |
| 2022 Q3 | 138.37 Million USD | -45.61% |
| 2022 Q2 | 254.43 Million USD | 118.32% |
| 2021 Q2 | 140.83 Million USD | 42.55% |
| 2021 Q3 | 235.41 Million USD | 67.15% |
| 2021 Q4 | 110.73 Million USD | -52.96% |
| 2021 FY | 585.77 Million USD | 343.78% |
| 2021 Q1 | 98.79 Million USD | -39.84% |
| 2020 Q3 | 5.32 Million USD | -97.69% |
| 2020 Q1 | -664 Million USD | -798.89% |
| 2020 Q2 | 230.77 Million USD | 134.75% |
| 2020 FY | -240.29 Million USD | -159.77% |
| 2020 Q4 | 164.22 Million USD | 2983.53% |
| 2019 Q2 | 98.61 Million USD | 33.13% |
| 2019 Q1 | 74.07 Million USD | -9.64% |
| 2019 FY | 402 Million USD | 211.09% |
| 2019 Q3 | 134.31 Million USD | 36.21% |
| 2019 Q4 | 95 Million USD | -29.27% |
| 2018 Q3 | 31.11 Million USD | -62.61% |
| 2018 Q4 | 81.97 Million USD | 163.42% |
| 2018 Q1 | -67.11 Million USD | 49.38% |
| 2018 FY | 129.22 Million USD | 153.02% |
| 2018 Q2 | 83.23 Million USD | 224.03% |
| 2017 Q2 | 7.2 Million USD | 105.4% |
| 2017 FY | -243.73 Million USD | -268.09% |
| 2017 Q1 | -133.3 Million USD | -416.79% |
| 2017 Q3 | 14.95 Million USD | 107.75% |
| 2017 Q4 | -132.58 Million USD | -986.4% |
| 2016 Q3 | 22.29 Million USD | -50.01% |
| 2016 Q2 | 44.58 Million USD | 23.72% |
| 2016 FY | 144.99 Million USD | 186.27% |
| 2016 Q1 | 36.03 Million USD | -44.62% |
| 2016 Q4 | 42.07 Million USD | 88.76% |
| 2015 Q4 | 65.08 Million USD | 64535.64% |
| 2015 Q2 | -7.39 Million USD | -6.62% |
| 2015 FY | 50.65 Million USD | 1154.35% |
| 2015 Q3 | -101 Thousand USD | 98.63% |
| 2015 Q1 | -6.93 Million USD | 72.94% |
| 2014 Q1 | -22.93 Million USD | -42.07% |
| 2014 Q3 | 69.94 Million USD | 367.09% |
| 2014 Q2 | -26.18 Million USD | -14.18% |
| 2014 Q4 | -25.62 Million USD | -136.64% |
| 2014 FY | -4.8 Million USD | 70.17% |
| 2013 Q4 | -16.14 Million USD | -22.45% |
| 2013 Q2 | 17.31 Million USD | 522.72% |
| 2013 Q1 | -4.09 Million USD | -113.54% |
| 2013 FY | -16.1 Million USD | -1502.61% |
| 2013 Q3 | -13.18 Million USD | -176.12% |
| 2012 Q2 | 15.21 Million USD | 144.52% |
| 2012 Q4 | 30.25 Million USD | 398.42% |
| 2012 Q3 | -10.13 Million USD | -166.61% |
| 2012 Q1 | -34.18 Million USD | 22.54% |
| 2012 FY | 1.14 Million USD | 100.8% |
| 2011 Q1 | -15.82 Million USD | -137.4% |
| 2011 FY | -143.18 Million USD | -1119.17% |
| 2011 Q4 | -44.13 Million USD | -4.83% |
| 2011 Q3 | -42.1 Million USD | -2.41% |
| 2011 Q2 | -41.11 Million USD | -159.8% |
| 2010 FY | 14.04 Million USD | 110.05% |
| 2010 Q4 | 42.31 Million USD | 291.83% |
| 2010 Q3 | -22.05 Million USD | -261.89% |
| 2010 Q2 | 13.62 Million USD | 168.7% |
| 2010 Q1 | -19.83 Million USD | 51.89% |
| 2009 Q4 | -41.22 Million USD | -30.6% |
| 2009 FY | -139.76 Million USD | 12.26% |
| 2009 Q1 | -34.24 Million USD | 19.74% |
| 2009 Q2 | -32.73 Million USD | 4.4% |
| 2009 Q3 | -31.56 Million USD | 3.59% |
| 2008 Q1 | -36.12 Million USD | -31.67% |
| 2008 Q4 | -42.66 Million USD | -7.22% |
| 2008 FY | -159.28 Million USD | -86.78% |
| 2008 Q2 | -40.7 Million USD | -12.67% |
| 2008 Q3 | -39.79 Million USD | 2.24% |
| 2007 Q1 | -20.28 Million USD | -3.7% |
| 2007 Q2 | -16.18 Million USD | 20.19% |
| 2007 Q3 | -21.37 Million USD | -32.05% |
| 2007 Q4 | -27.43 Million USD | -28.35% |
| 2007 FY | -85.28 Million USD | -10.95% |
| 2006 Q2 | -19.18 Million USD | 14.26% |
| 2006 Q4 | -19.55 Million USD | -24.13% |
| 2006 Q3 | -15.75 Million USD | 17.85% |
| 2006 Q1 | -22.36 Million USD | 15.89% |
| 2006 FY | -76.86 Million USD | 23.73% |
| 2005 Q1 | -17.99 Million USD | 47.22% |
| 2005 Q4 | -26.59 Million USD | 8.73% |
| 2005 Q2 | -27.06 Million USD | -50.39% |
| 2005 Q3 | -29.13 Million USD | -7.68% |
| 2005 FY | -100.78 Million USD | 32.29% |
| 2004 FY | -148.85 Million USD | 0.3% |
| 2004 Q1 | -33.47 Million USD | 11.98% |
| 2004 Q2 | -60.94 Million USD | -82.04% |
| 2004 Q3 | -20.34 Million USD | 66.62% |
| 2004 Q4 | -34.09 Million USD | -67.62% |
| 2003 Q2 | -26.81 Million USD | 50.59% |
| 2003 Q4 | -38.03 Million USD | -26.07% |
| 2003 Q3 | -30.17 Million USD | -12.5% |
| 2003 Q1 | -54.27 Million USD | -189.15% |
| 2003 FY | -149.29 Million USD | -52.49% |
| 2002 Q4 | -18.77 Million USD | 49.9% |
| 2002 Q2 | -22.77 Million USD | -20.53% |
| 2002 FY | -97.9 Million USD | -51.33% |
| 2002 Q3 | -37.46 Million USD | -64.48% |
| 2002 Q1 | -18.89 Million USD | -31.45% |
| 2001 Q3 | -11.22 Million USD | 36.54% |
| 2001 Q2 | -17.69 Million USD | 17.31% |
| 2001 FY | -64.69 Million USD | -3.37% |
| 2001 Q4 | -14.37 Million USD | -28.03% |
| 2001 Q1 | -21.39 Million USD | -25.5% |
| 2000 Q3 | -15.74 Million USD | -9.41% |
| 2000 Q2 | -14.39 Million USD | 6.55% |
| 2000 FY | -62.59 Million USD | -131.81% |
| 2000 Q1 | -15.4 Million USD | -126.49% |
| 2000 Q4 | -17.05 Million USD | -8.29% |
| 1999 Q2 | -7.7 Million USD | -285.0% |
| 1999 Q3 | -10.5 Million USD | -36.36% |
| 1999 Q4 | -6.8 Million USD | 35.24% |
| 1999 Q1 | -2 Million USD | -350.0% |
| 1999 FY | -27 Million USD | -321.31% |
| 1998 Q4 | 800 Thousand USD | -73.33% |
| 1998 Q2 | 4.3 Million USD | 4.88% |
| 1998 FY | 12.2 Million USD | 64.86% |
| 1998 Q1 | 4.1 Million USD | 20.59% |
| 1998 Q3 | 3 Million USD | -30.23% |
| 1997 Q3 | 1.9 Million USD | 26.67% |
| 1997 FY | 7.4 Million USD | 225.42% |
| 1997 Q4 | 3.4 Million USD | 78.95% |
| 1997 Q1 | 600 Thousand USD | 400.0% |
| 1997 Q2 | 1.5 Million USD | 150.0% |
| 1996 Q1 | -2.8 Million USD | -12.0% |
| 1996 Q3 | -700 Thousand USD | 68.18% |
| 1996 FY | -5.9 Million USD | 46.36% |
| 1996 Q4 | -200 Thousand USD | 71.43% |
| 1996 Q2 | -2.2 Million USD | 21.43% |
| 1995 Q3 | -3.1 Million USD | 0.0% |
| 1995 Q2 | -3.1 Million USD | -40.91% |
| 1995 Q4 | -2.5 Million USD | 19.35% |
| 1995 Q1 | -2.2 Million USD | 48.84% |
| 1995 FY | -11 Million USD | 9.09% |
| 1994 Q1 | -2.2 Million USD | -69.23% |
| 1994 Q2 | -2.4 Million USD | -9.09% |
| 1994 FY | -12.1 Million USD | -146.94% |
| 1994 Q4 | -4.3 Million USD | -38.71% |
| 1994 Q3 | -3.1 Million USD | -29.17% |
| 1993 FY | -4.9 Million USD | 0.0% |
| 1993 Q3 | -1.2 Million USD | 0.0% |
| 1993 Q4 | -1.3 Million USD | -8.33% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 90.953% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 258.505% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 324.823% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 610.741% |
| uniQure N.V. | -282.87 Million USD | 319.367% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 944.321% |
| bluebird bio, Inc. | -244.26 Million USD | 354.041% |
| Imunon, Inc. | -21.03 Million USD | 3050.605% |
| Dynavax Technologies Corporation | -37.02 Million USD | 1775.826% |
| Editas Medicine, Inc. | -169.18 Million USD | 466.782% |
| Illumina, Inc. | -1.06 Billion USD | 158.047% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 234.733% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 68.613% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 42.929% |
| Myriad Genetics, Inc. | -123.7 Million USD | 601.637% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | -147.32% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 331.691% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 11876.903% |
| Verastem, Inc. | -92.08 Million USD | 773.868% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 104.408% |
| Waters Corporation | 817.67 Million USD | 24.111% |
| Biogen Inc. | 1.29 Billion USD | 52.15% |
| Nektar Therapeutics | -137.42 Million USD | 551.537% |
| Perrigo Company plc | 151.9 Million USD | -308.509% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 1476.58% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 660.977% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 1489.225% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | -219.133% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 326.465% |
| Evolus, Inc. | -49.23 Million USD | 1360.384% |
| Adicet Bio, Inc. | -152.03 Million USD | 508.138% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 737.371% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 84.667% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 498.89% |
| FibroGen, Inc. | -281.81 Million USD | 320.189% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 54.035% |
| OPKO Health, Inc. | -157.02 Million USD | 495.186% |
| Homology Medicines, Inc. | -48.25 Million USD | 1385.929% |
| Geron Corporation | -193.94 Million USD | 419.951% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 319.908% |
| Exelixis, Inc. | 170.88 Million USD | -263.124% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 715.435% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 1212.93% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 220.422% |
| Zoetis Inc. | 3.06 Billion USD | 79.781% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 367.67% |
| Abeona Therapeutics Inc. | -48.2 Million USD | 1387.396% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 85.594% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 1684.872% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 275.423% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | -478.406% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | -83.819% |
| Blueprint Medicines Corporation | -486.27 Million USD | 227.607% |
| Insmed Incorporated | -709.62 Million USD | 187.444% |
| TG Therapeutics, Inc. | 20.63 Million USD | -2907.44% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 185.425% |